Skip to main content

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program


Across the MVC development program, patients who received MVC-containing regimens experienced greater increases in CD4+ cell counts than those observed in comparator arms in primary analyses. Here we present longer term immunological data from this program.

Material and methods

Long-term (96 week) data from subjects with CCR5-tropic HIV infection in the following ongoing MVC studies were included in the analysis: (1) MOTIVATE study (MVC QD and BID vs placebo (PBO), each combined with optimized background therapy in treatment-experienced [TE] subjects); and (2) MERIT study (MVC BID vs EFV, each combined with ZDV/3TC in treatment-naïve [TN] subjects). Additionally, interim week 24 data from the ongoing 96-week 1078 study (MVC QD vs TDF/FTC, each combined with ATV/r in TN subjects) were summarized. Descriptive statistics are presented for data at baseline and at week 96 (MERIT/MOTIVATE) or week 24 (1078) pertaining to change in CD4+ and CD8+ cells.


Greater increases in CD4+ cells in MVC-containing groups persisted through 96 weeks in the MOTIVATE and MERIT studies, and through 24 weeks in the 1078 study (Table 1). Similarly, changes in CD8+ cells from baseline to weeks 96 or 24 favored MVC-containing regimens in all three studies. In a combined LOCF analysis of patients from all three studies at week 24, CD4+ counts increased by a median 100.5 cells/µL in 1260 recipients of MVC-containing regimens, compared with 84.5 cells/µL in 631 recipients of comparator regimens; CD8+ counts increased by a median 153 cells/µL in the MVC group, compared with a decrease of 61 cells/µL in the comparator group. At week 96, a combined analysis of patients from the MOTIVATE and MERIT studies showed median CD4+ increases from baseline of 129.5 and 100.3 cells/µL in the MVC (N=1177) and comparator (N=554) groups, respectively; CD8+ changes were 96 and -72 cells/µL, respectively. In all studies, differences in CD4+ and CD8+ counts between treatment groups were independent of differences in viral load changes (data not shown).

Table 1


Greater increases in CD4+ and CD8+ counts were consistently achieved with MVC-containing regimens, compared to regimens without MVC, and persisted through at least 2 years of therapy in both TN and TE patients. These differences were independent of changes in HIV-1 RNA and are evident with multiple different MVC-containing regimens.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Lazzarin, A., Sierra-Madero, J., Battegay, M. et al. Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program. JIAS 13 (Suppl 4), O45 (2010).

Download citation

  • Published:

  • DOI:


  • Great Increase
  • Load Change
  • Maraviroc
  • Background Therapy
  • Clinical Development Program